REFERENCES
- Phillips CJ. Economic analysis of long-term and reversible contraceptives: focus on Implanon1. Pharma- coeconomics 2000;17:209–21
- Edward J, Moore A. Implanon1: a review of clinical studies. J Fam Planning 1999;24:3–16
- Davie JE, Walling MR, Mansour DJ, et al. Impact of patient counselling on acceptance of the levonorgestrel contraceptive implant in the UK. Clin Ther 1996;18:150–9
- Glasier A. Implantable contraception for women: effectiveness, discontinuation rates and return of fertility and outcome of pregnancies. Contraception 2002;65:29–37
- Croxatto H. Clinical profile of Implanon1: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5(Suppl 2):21–8
- Smith A, Reuter S. An assessment of use of Implanon1 in 3 community services. Fam Plann Reprod Healthcare 2002;28:193–5
- Alvarez F, Brache V, Faundes A, et al. Non-menstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 2002;65:63–74
- Meirik O, Fraser IS, d’Arcangues C. WHO consultation on implantable contraception for women. Hum Reprod Update 2003;9:1–11
- Urbancsek J. An integrated analysis of non-menstrual adverse events with Implanon1. Contraception 1998; 58:1095–155
- International Collaborative Post-marketing Surveillance of Norplant. Post marketing Surveillance of Norplant1 contraceptive implants. II. Contraception 2001;63:1157–209
- Blain S, Lovelady J, Olon E, et al. Reasons for commencing and discontinuing Norplant contraception. Br J Fam Plann 1995;21(Suppl):17–21